(3R,3aS)-3-ethynyl-3-hydroxy-3a-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1H-indene-5-carbaldehyde | 1021539-25-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (3R,3aS)-3-ethynyl-3-hydroxy-3a-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1H-indene-5-carbaldehyde
• 英文别名: (3R,3αS)-3-ethynyl-3-hydroxy-3α-methyl-6-oxo-2,3,3α,4,5,6-hexahydro-1H-indene-5-carbaldehyde；(3R,3aS)-3-ethynyl-3-hydroxy-3a-methyl-6-oxo-1,2,4,5-tetrahydroindene-5-carbaldehyde
• CAS: 1021539-25-2
• 化学式: C₁₃H₁₄O₃
• 分子量: 218.252
• InChiKey: NIEAKKXXWVNWJM-AXRFISIWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3R,3aS)-3-ethynyl-3-hydroxy-3a-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1H-indene-5-carbaldehyde 、 4-氟苯肼盐酸盐 在 sodium acetate 、 碳酸氢钠 作用下， 以 溶剂黄146 、 水 为溶剂， 反应 1.0h， 以94%的产率得到(4aS,5R)-5-ethynyl-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-ol
  参考文献：
  名称：

  [EN] PROCESS FOR MAKING GLUCOCORTICOID RECEPTOR LIGANDS
  [FR] PROCÉDÉ DE PRÉPARATION DE LIGANDS DU RÉCEPTEUR DES GLUCOCORTICOÏDES

  摘要：

  这项发明涵盖了一种制备2-[1-苯基-5-羟基-4α-甲基-六氢环戊基吲唑-5-基]乙基苯衍生物的过程，这些衍生物是糖皮质激素受体配体，用于治疗炎症和免疫性疾病。

  公开号：

  WO2009054925A1
• 作为产物：
  描述：

  (3S,3aS)-3-hydroxy-3a-methyl-6-oxo-3-((trimethylsilyl)ethynyl)-2,3,3a,4,5,6-hexahydro-1H-indene-5-carbaldehyde 在 potassium carbonate 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 1.5h， 以75%的产率得到(3R,3aS)-3-ethynyl-3-hydroxy-3a-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1H-indene-5-carbaldehyde
  参考文献：
  名称：

  [EN] PROCESS FOR MAKING GLUCOCORTICOID RECEPTOR LIGANDS
  [FR] PROCÉDÉ DE PRÉPARATION DE LIGANDS DU RÉCEPTEUR DES GLUCOCORTICOÏDES

  摘要：

  这项发明涵盖了一种制备2-[1-苯基-5-羟基-4α-甲基-六氢环戊基吲唑-5-基]乙基苯衍生物的过程，这些衍生物是糖皮质激素受体配体，用于治疗炎症和免疫性疾病。

  公开号：

  WO2009054925A1

文献信息

• PROCESS FOR MAKING GLUCOCORTICOID RECEPTOR LIGANDS
  申请人：Chen Qinghao

  公开号：US20100228036A1

  公开（公告）日：2010-09-09

  The invention encompasses a process for making 2-[1-phenyl-5-hydroxy-4alpha-methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives, which are glucocorticoid receptor ligands, useful for the treatment of inflammatory and immunological diseases.

  本发明涵盖了一种制备2-[1-苯基-5-羟基-4α-甲基-六氢环戊-[f]吲唑-5-基]乙基苯基衍生物的方法，该衍生物是糖皮质激素受体配体，可用于治疗炎症和免疫性疾病。
• 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
  申请人：Bungard Christopher J.

  公开号：US20100311709A1

  公开（公告）日：2010-12-09

  The present invention is directed to 2-[ 1 -phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives of formula I (I) as glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

  本发明涉及公式I（I）的2-[1-苯基-5-羟基或甲氧基-4α-甲基-六氢环戊[f]吲唑-5-基]乙基苯基衍生物，作为糖皮质激素受体配体，用于治疗各种自身免疫和炎症性疾病或症状。还包括制药组合物和使用方法。
• WO2008/51532
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of selective glucocorticoid receptor modulator MK-5932
  作者：Christopher J. Bungard、George D. Hartman、Jesse J. Manikowski、James J. Perkins、Chang Bai、Philip E. Brandish、Danielle H. Euler、James C. Hershey、Azriel Schmidt、Yulin Fang、Ryan T. Norcross、Tom H. Rushmore、Charles D. Thompson、Robert S. Meissner

  DOI：10.1016/j.bmc.2011.10.054

  日期：2011.12

  A series of partial agonists of the Glucocorticoid Receptor were prepared targeting reduced transactivation activity, while maintaining significant transrepression activity. Incorporation of an ortho-aryl amide produced compounds with the desired in vitro profile. Bioreactors consisting of Suspension cultures of Sf21 cells co expressing a CYP3A4 and NADPH-cytochrome P450 oxireductase were used to prepare the major metabolites of these compounds and revealed that oxidative N-dealkylation provided a pathway for formation of metabolites that were more agonistic than the parent partial agonists. Oxidative N-dealkylation was blocked in a new series of compounds, however oxidation alone was capable of producing full agonist metabolites. Incorporation of an ortho-primary amide and utilization of fluorine to modulate agonism afforded partial agonist MK-5932. Synthesis of the major metabolites of MK-5932 using bioreactor technology revealed that no significant GR-active metabolites were formed. Orally administered MK-5932 displayed anti-inflammatory efficacy in a Rat Oxazolone-induced chronic dermatitis model, while sparing plasma insulin. (C) 2011 Elsevier Ltd. All rights reserved.
• US8119681B2
  申请人：——

  公开号：US8119681B2

  公开（公告）日：2012-02-21